Identification of chemical constituents of Smilax glabra Roxb. and comparative study on pharmacokinetics of 12 main bioactive components in normal and hyperuricemia rats by UPLC-Q-Exactive Orbitrap-HRMS method

IF 3.1 3区医学 Q2 CHEMISTRY, ANALYTICAL

Journal of pharmaceutical and biomedical analysis Pub Date : 2025-09-15 DOI:10.1016/j.jpba.2025.117149

Shiyang Li , Changyu Long , Mi Li , Lingyu Tian , Rongsheng Li , Jing Guo , Zhenyu Xuan

{"title":"Identification of chemical constituents of Smilax glabra Roxb. and comparative study on pharmacokinetics of 12 main bioactive components in normal and hyperuricemia rats by UPLC-Q-Exactive Orbitrap-HRMS method","authors":"Shiyang Li , Changyu Long , Mi Li , Lingyu Tian , Rongsheng Li , Jing Guo , Zhenyu Xuan","doi":"10.1016/j.jpba.2025.117149","DOIUrl":null,"url":null,"abstract":"<div><div><em>Smilax glabra</em> (<em>S. glabra</em>), a dual-purpose medicinal herb, demonstrates anti-hyperuricemic potential, but its active constituents remain unclear. Here, we systematically characterized its chemical profile and compared pharmacokinetics between normal and hyperuricemic (HUA) rats. Using Ultra-Performance Liquid Chromatography coupled with Q-Exactive Orbitrap High-Resolution Mass Spectrometry (UPLC-Q-Exactive Orbitrap-HRMS), we identified 89 compounds, with 12 quantitatively analyzed by a validated UPLC-MS/MS method (precision RSD <15 %, accuracy 85–115 %). The pharmacokinetic analysis demonstrated that most compounds achieved peak plasma concentrations within 0.5–3 h with relatively short elimination half-lives, while comparative assessment revealed significantly increased systemic exposure and prolonged time for seven key constituents (caffeic acid, neoastilbin, astilbin, neoisoastilbin, isoastilbin, engeletin, and quercetin) in HUA rats. The results of this study provide a direction and basis for further revealing the active components of <em>S. glabra</em> in the treatment of HUA.</div></div>","PeriodicalId":16685,"journal":{"name":"Journal of pharmaceutical and biomedical analysis","volume":"267 ","pages":"Article 117149"},"PeriodicalIF":3.1000,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmaceutical and biomedical analysis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S073170852500490X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, ANALYTICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Smilax glabra (S. glabra), a dual-purpose medicinal herb, demonstrates anti-hyperuricemic potential, but its active constituents remain unclear. Here, we systematically characterized its chemical profile and compared pharmacokinetics between normal and hyperuricemic (HUA) rats. Using Ultra-Performance Liquid Chromatography coupled with Q-Exactive Orbitrap High-Resolution Mass Spectrometry (UPLC-Q-Exactive Orbitrap-HRMS), we identified 89 compounds, with 12 quantitatively analyzed by a validated UPLC-MS/MS method (precision RSD <15 %, accuracy 85–115 %). The pharmacokinetic analysis demonstrated that most compounds achieved peak plasma concentrations within 0.5–3 h with relatively short elimination half-lives, while comparative assessment revealed significantly increased systemic exposure and prolonged time for seven key constituents (caffeic acid, neoastilbin, astilbin, neoisoastilbin, isoastilbin, engeletin, and quercetin) in HUA rats. The results of this study provide a direction and basis for further revealing the active components of S. glabra in the treatment of HUA.

查看原文本刊更多论文

菝葜化学成分的鉴定。采用UPLC-Q-Exactive Orbitrap-HRMS法对12种主要生物活性成分在正常大鼠和高尿酸血症大鼠体内的药动学进行比较研究。

菝葜（S. glabra）是一种具有抗高尿酸血症潜力的双重药用植物，但其有效成分尚不清楚。在这里，我们系统地表征了其化学特征，并比较了正常和高尿酸血症（HUA）大鼠的药代动力学。采用超高效液相色谱-Q-Exactive Orbitrap- hrms （UPLC-Q-Exactive Orbitrap- hrms）技术，共鉴定出89种化合物，其中12种化合物通过经过验证的UPLC-MS/MS方法（精密度RSD）进行了定量分析

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of pharmaceutical and biomedical analysis 医学-分析化学

CiteScore

6.70

自引率

5.90%

发文量

588

审稿时长

37 days

期刊介绍： This journal is an international medium directed towards the needs of academic, clinical, government and industrial analysis by publishing original research reports and critical reviews on pharmaceutical and biomedical analysis. It covers the interdisciplinary aspects of analysis in the pharmaceutical, biomedical and clinical sciences, including developments in analytical methodology, instrumentation, computation and interpretation. Submissions on novel applications focusing on drug purity and stability studies, pharmacokinetics, therapeutic monitoring, metabolic profiling; drug-related aspects of analytical biochemistry and forensic toxicology; quality assurance in the pharmaceutical industry are also welcome. Studies from areas of well established and poorly selective methods, such as UV-VIS spectrophotometry (including derivative and multi-wavelength measurements), basic electroanalytical (potentiometric, polarographic and voltammetric) methods, fluorimetry, flow-injection analysis, etc. are accepted for publication in exceptional cases only, if a unique and substantial advantage over presently known systems is demonstrated. The same applies to the assay of simple drug formulations by any kind of methods and the determination of drugs in biological samples based merely on spiked samples. Drug purity/stability studies should contain information on the structure elucidation of the impurities/degradants.